Overview Remepy has published new mechanistic findings in npj Parkinson’s Disease demonstrating how Hybridopa, its Hybrid Drug for Parkinson’s disease, may improve ...
Overview GAIA’s digital therapeutic deprexis is now reimbursable in Switzerland for patients with mild to moderate depression and recurrent depressive disorders under the country’s man...
Overview PsychPlus has acquired Koa Health to strengthen its integrated, technology-enabled mental health platform and expand access to digital behavioral healthcare globally.&nbs...
Overview Shionogi has launched Endeavorride, Japan’s first Software as a Medical Device (SaMD) digital therapeutic app for the adjunctive treatment of pediatric ADHD. The app, l...
Overview A secondary analysis of a randomized controlled trial published in Behaviour Research and Therapy found that somnovia, GAIA’s digital insomnia therapy, primarily imp...
Overview Remepy announced positive Phase IIa results for Hybridopa, its Hybrid Drug combining levodopa with an AI-driven digital therapeutic, demonstrating significant improvement...
Overview Remepy has entered a collaboration with Merck KGaA, Darmstadt, Germany, to explore the development of Hybrid Drugs that combine pharmacological therapies with AI-enabled digital th...
Overview The News DarioHealth announced the publication of a peer-reviewed study in JMIR Formative Research evaluating the real-world impact of its digital behavioral&n...
Overview Cerebral has acquired Inflow, a personalized ADHD digital therapeutic app, to strengthen its integrated mental healthcare platform and expand continuous support for patients w...
Overview GAIA reported positive results from a randomized controlled trial published in Psychological Medicine, demonstrating that attexis significantly reduced ADH...
